GO:2000524 negative regulation of T cell costimulation: Immune Checkpoint Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000524 (negative regulation of T cell costimulation) describes any process that stops, prevents, or reduces the frequency, rate, or extent of T cell costimulation, a critical brake on T cell activation.
• Negative regulators of costimulation include phosphatases such as HePTP, kinases such as GSK-3, and lipid receptors such as GPR174, which act downstream of TCR and costimulatory signals.
• This process is essential for maintaining immune tolerance and preventing autoimmunity, but it also limits anti-tumor immunity and CAR-T efficacy.
• Tumor-derived factors such as PGE2 can disrupt IL-2 signaling and mitochondrial function, indirectly suppressing costimulation-dependent T cell expansion.
• CAR-negative T cells can influence the efficacy and safety of CAR-T therapies, highlighting the clinical relevance of costimulation regulation.
• Experimental approaches to study GO:2000524 include CRISPR knockout, point mutation, knock-in, overexpression, and CRISPR library screening, supported by RNA-seq, proteomics, and functional assays.
Description
T cell costimulation is a fundamental process that provides the second signal required for full T cell activation, proliferation, and effector function. Negative regulation of T cell costimulation (GO:2000524) encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of this costimulatory signaling. This regulatory mechanism is crucial for balancing protective immunity against pathogens with the prevention of excessive or autoreactive T cell responses. Dysregulation of this process contributes to autoimmune diseases, chronic infections, and cancer immune evasion. Understanding the molecular players and pathways involved in negative regulation of T cell costimulation is therefore essential for developing targeted immunotherapies. This article integrates authoritative QuickGO data with real PubMed literature to provide a comprehensive overview of the genes, mechanisms, and research methods relevant to GO:2000524.
negative regulation of T cell costimulation At A Glance
| GO ID | GO:2000524 |
|---|---|
| GO term | negative regulation of T cell costimulation |
| Ontology | biological_process |
| Synonym | negative regulation of T cell co-stimulation; negative regulation of T-cell co-stimulation; negative regulation of T-cell costimulation; negative regulation of T lymphocyte costimulation; negative regulation of T-lymphocyte costimulation |
| Major function | Dampening or preventing the costimulatory signals required for full T cell activation, thereby maintaining immune homeostasis and preventing autoimmunity. |
| Key regulators | HePTP (PTPN7), GSK-3, GPR174, EBI2 (GPR183), HDAC4/HDAC7, low-affinity IL-2 receptors. |
| Associated diseases | Autoimmunity, cancer immune evasion, and CAR-T therapy resistance. |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, CRISPR library screening, RNA-seq, proteomics, and functional T cell assays. |
What Is GO:2000524?
GO:2000524, negative regulation of T cell costimulation, is a biological process defined as any process that stops, prevents, or reduces the frequency, rate, or extent of T cell costimulation. In other words, it includes molecular events that dampen or shut down the secondary signals required for full T cell activation, thereby acting as a checkpoint in adaptive immunity.
Why Is negative regulation of T cell costimulation Important in Cell Biology?
Negative regulation of T cell costimulation is a central mechanism for maintaining immune tolerance and preventing autoimmunity, while also shaping the efficacy of cancer immunotherapies. Dysregulation of this process can lead to uncontrolled T cell activation or, conversely, insufficient anti-tumor immunity. Understanding the molecular players and pathways involved is critical for designing interventions that can either enhance or suppress T cell responses in diseases such as cancer, autoimmunity, and chronic infections.
• Prevents autoimmunity by dampening T cell costimulation and avoiding excessive T cell activation.
• Limits anti-tumor immunity, contributing to cancer immune evasion.
• Influences the efficacy and safety of CAR-T cell therapies.
• Modulates T follicular helper (Tfh) cell fate and germinal center responses.
• Regulates Th17 cell differentiation and IL-17 production.
• Controls T cell proliferation and IL-2 production via GSK-3 and low-affinity IL-2 receptors.
• Involves lipid mediators such as lysophosphatidylserine and PGE2 that suppress T cell activation.
• Provides targets for therapeutic intervention in autoimmune diseases and cancer.
• Serves as a model for studying signal transduction checkpoints in T cells.
• Enables CRISPR-based functional genomics to identify novel regulators.
What Happens During negative regulation of T cell costimulation?
Initiation by coinhibitory receptors and phosphatases
In simple terms: Certain receptors and enzymes put the brakes on T cell activation.
Negative regulation of T cell costimulation can be initiated by coinhibitory receptors and intracellular phosphatases. For example, hematopoietic tyrosine phosphatase (HePTP) negatively regulates T cell antigen receptor signal transduction, thereby reducing costimulatory signals. Similarly, the lipid receptor GPR174, when activated by lysophosphatidylserine, suppresses T cell activation via Gαs proteins.
Amplification through kinases and transcription factors
In simple terms: Kinases and transcription factors can strengthen the inhibitory signal.
The serine/threonine kinase GSK-3 negatively regulates T cell proliferation and interleukin 2 production, acting as a downstream amplifier of inhibitory signals. Class IIa HDAC4 and HDAC7 cooperatively regulate gene transcription in Th17 cell differentiation, influencing the balance between activation and suppression.
Modulation by metabolic and cytokine signals
In simple terms: Metabolic factors and cytokines can also dampen costimulation.
Prostaglandin E2 (PGE2) inhibits tumor-infiltrating lymphocyte expansion by disrupting IL-2 signalling and mitochondrial function, indirectly suppressing costimulation-dependent T cell activation. Low-affinity interleukin 2 receptors provide evidence for negative regulation of T cell growth, further limiting costimulatory responses.
Integration with Tfh and CAR-T contexts
In simple terms: This regulation also affects specialized T cell subsets and engineered T cells.
EBI2 (GPR183) augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells, illustrating how negative regulation of costimulation can shape T cell differentiation. In CAR-T therapies, CAR-negative T cells can influence efficacy and safety, highlighting the clinical importance of costimulation regulation.
Key Genes Involved in GO:2000524 negative regulation of T cell costimulation
The following genes and proteins are experimentally implicated in negative regulation of T cell costimulation (GO:2000524) based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTPN7 (HePTP) | Protein tyrosine phosphatase that negatively regulates TCR signal transduction | Target for modulating early T cell signaling |
| GSK3A/GSK3B | Serine/threonine kinases that negatively regulate T cell proliferation and IL-2 production | Potential target for enhancing or suppressing T cell responses |
| GPR174 | G protein-coupled receptor that suppresses T cell activation via Gαs upon lysophosphatidylserine binding | Lipid-mediated immune regulation |
| GPR183 (EBI2) | Receptor that augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells | Tfh differentiation and germinal center responses |
| HDAC4 | Class IIa HDAC that cooperatively regulates gene transcription in Th17 differentiation | Epigenetic regulation of T cell subsets |
| HDAC7 | Class IIa HDAC that cooperatively regulates gene transcription in Th17 differentiation | Epigenetic regulation of T cell subsets |
| IL2RA (CD25) | Low-affinity IL-2 receptor subunit involved in negative regulation of T cell growth | Cytokine signaling in T cell homeostasis |
| IL2RB (CD122) | Low-affinity IL-2 receptor subunit involved in negative regulation of T cell growth | Cytokine signaling in T cell homeostasis |
| PTGER2/PTGER4 | PGE2 receptors that mediate inhibition of TIL expansion via IL-2 signaling disruption | Tumor microenvironment immunosuppression |
| CAR (transgene) | Chimeric antigen receptor; CAR-negative T cells influence CAR-T efficacy and safety | Engineered T cell therapy |
| GNAI/GNAS | G proteins mediating GPR174 signaling | GPCR signaling in T cells |
| PTPN11 (SHP2) | Potential phosphatase in TCR signaling (implied by HePTP studies) | TCR signal modulation |
| AKT | Downstream kinase affected by GSK-3 and IL-2 signaling | T cell survival and proliferation |
| MTOR | Metabolic regulator impacted by PGE2 and IL-2 signaling | T cell metabolism and function |
| FOXP3 | Regulatory T cell transcription factor potentially influenced by costimulation (implied) | Treg biology |
| BCL6 | Tfh transcription factor downstream of EBI2 | Tfh differentiation |
| RORC (RORγt) | Th17 transcription factor regulated by HDAC4/7 | Th17 differentiation |
| IL17A | Effector cytokine of Th17 cells | Autoimmune inflammation |
How Is negative regulation of T cell costimulation Regulated?
Negative regulation of T cell costimulation is itself regulated at multiple levels. GSK-3 activity can be modulated by upstream kinases such as Akt, which is influenced by IL-2 signaling. PGE2 disrupts IL-2 signaling and mitochondrial function, thereby indirectly affecting costimulation-dependent pathways. GPR174 signaling via Gαs proteins provides a lipid-mediated inhibitory input. Additionally, HDAC4 and HDAC7 regulate transcription in Th17 cells, linking epigenetic modifications to costimulation outcomes. These layers of regulation allow fine-tuning of T cell responses in different contexts.
negative regulation of T cell costimulation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTPN7 (HePTP) | Autoimmunity, TCR signaling dysregulation | Knockout mice or Jurkat T cells with PTPN7 KO |
| GSK3A/GSK3B | Autoimmunity, T cell proliferation defects | GSK-3 inhibitor treatment or CRISPR KO in primary T cells |
| GPR174 | Autoimmunity, lipid-mediated immunosuppression | GPR174 KO mice or T cells |
| PTGER2/PTGER4 | Cancer immune evasion, TIL dysfunction | PGE2-treated TILs or receptor KO |
| HDAC4/HDAC7 | Th17-mediated autoimmunity | Conditional KO in Th17 cells |
Cancer immune evasion
Tumors can exploit negative regulation of T cell costimulation to evade immune attack. PGE2 produced in the tumor microenvironment inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function, thereby suppressing costimulation-dependent anti-tumor responses. CAR-negative T cells can also influence the efficacy of CAR-T therapies, highlighting the need to understand costimulation checkpoints.
Autoimmunity
Defects in negative regulation of T cell costimulation can lead to excessive T cell activation and autoimmunity. For example, loss of HePTP function may enhance TCR signaling and promote autoreactive T cell responses. Similarly, dysregulated GSK-3 or GPR174 signaling could contribute to autoimmune pathology.
Chronic infections and T cell exhaustion
Persistent antigen stimulation can upregulate negative regulators of costimulation, leading to T cell exhaustion. Low-affinity IL-2 receptors and GSK-3 may contribute to reduced T cell proliferation and effector function in chronic infections.
From negative regulation of T cell costimulation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of HePTP enhance T cell costimulation? | PTPN7 knockout in Jurkat or primary T cells |
| Can GSK-3 inhibition boost T cell proliferation? | GSK-3 point mutation or knockout in mouse T cells |
| How does GPR174 signaling suppress T cell activation? | GPR174 knockout or overexpression in T cells |
| What is the role of EBI2 in Tfh differentiation? | EBI2 knock-in or knockout in mouse models |
| Do HDAC4/7 regulate Th17 costimulation? | HDAC4/7 double knockout in Th17 cells |
| How does PGE2 affect TIL expansion? | PTGER2/4 knockout or overexpression in TILs |
How to Study the negative regulation of T cell costimulation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene essentiality for costimulation | Identify novel negative regulators |
| RNA-seq | Transcriptional changes | Assess impact of GSK-3 or HDAC inhibition |
| Phosphoproteomics | Signaling pathway activity | Study HePTP or GPR174 downstream effects |
| Flow cytometry | Surface markers and cytokine production | Measure T cell activation and proliferation |
| Seahorse assay | Mitochondrial function | Evaluate PGE2 effects on TILs |
| ELISA | Cytokine secretion | Quantify IL-2 and IL-17 |
| CRISPR interference (CRISPRi) | Gene repression | Fine-tune costimulation regulators |
| Base editing | Point mutations | Model disease-associated variants |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify genes whose loss enhances or suppresses T cell costimulation. Such screens have been used to uncover regulators of T cell activation and are applicable to GO:2000524.
RNA-seq and transcriptomics
RNA sequencing can reveal transcriptional changes in T cells upon modulation of negative regulators such as GSK-3 or HDAC4/7.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics can quantify signaling changes downstream of HePTP or GPR174, providing insights into costimulation pathways.
Functional T cell assays
Proliferation, IL-2 production, and cytotoxicity assays are standard to measure the impact of negative regulators on T cell costimulation.
How CRISPR Can Be Used to Study GO:2000524 negative regulation of T cell costimulation
Knockout
CRISPR knockout of genes such as PTPN7, GSK3A/B, or GPR174 can reveal their role in negative regulation of T cell costimulation. For example, PTPN7 knockout enhances TCR signaling, while GSK-3 knockout increases T cell proliferation.
Point Mutation
Point mutations can mimic disease-associated variants or inactivate catalytic domains. For instance, mutating the phosphatase domain of HePTP can abolish its negative regulatory function.
Knock-in
Knock-in of tagged or reporter constructs allows tracking of negative regulators in primary T cells. EBI2 knock-in mice have been used to study Tfh differentiation.
Overexpression
Overexpression of negative regulators such as GPR174 or HDAC4/7 can suppress T cell costimulation, providing gain-of-function models.
How EDITGENE Supports negative regulation of T cell costimulation Research
Researchers studying negative regulation of T cell costimulation-related genes often need to determine whether a candidate gene is causally involved in dampening T cell activation. EDITGENE provides a comprehensive suite of CRISPR services to enable such functional studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of T cell costimulation research.
Frequently Asked Questions About negative regulation of T cell costimulation
What is GO:2000524?
GO:2000524 is the Gene Ontology term for negative regulation of T cell costimulation, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of T cell costimulation.
What genes are involved in negative regulation of T cell costimulation?
Key genes include PTPN7 (HePTP), GSK3A/B, GPR174, GPR183 (EBI2), HDAC4, HDAC7, IL2RA, IL2RB, and PTGER2/4, among others.
How does GSK-3 negatively regulate T cell costimulation?
GSK-3 is a serine/threonine kinase that negatively regulates T cell proliferation and interleukin 2 production, thereby dampening costimulatory signals.
What is the role of HePTP in T cell costimulation?
HePTP (PTPN7) is a hematopoietic tyrosine phosphatase that negatively regulates T cell antigen receptor signal transduction, reducing costimulatory signaling.
How does GPR174 suppress T cell activation?
GPR174, upon binding lysophosphatidylserine, suppresses T cell activation via Gαs proteins, contributing to negative regulation of costimulation.
What diseases are associated with dysregulated negative regulation of T cell costimulation?
Dysregulation is linked to autoimmunity, cancer immune evasion, and chronic infections, as well as CAR-T therapy outcomes.
How can CRISPR be used to study negative regulation of T cell costimulation?
CRISPR knockout, point mutation, knock-in, and overexpression can be used to manipulate candidate genes and assess their effects on T cell activation and proliferation.
What experimental models are suitable for studying GO:2000524?
Jurkat cells, primary human or mouse T cells, and mouse models with conditional knockouts are commonly used.
What is the impact of PGE2 on T cell costimulation?
PGE2 inhibits tumor-infiltrating lymphocyte expansion by disrupting IL-2 signalling and mitochondrial function, indirectly suppressing costimulation.
How does EBI2 influence Tfh cells?
EBI2 (GPR183) augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells, illustrating a role in negative regulation of costimulation.
Conclusion
Negative regulation of T cell costimulation (GO:2000524) is a critical biological process that maintains immune homeostasis and shapes responses to cancer and autoimmunity. The genes and pathways involved, such as HePTP, GSK-3, GPR174, and HDAC4/7, provide promising targets for therapeutic intervention. Advances in CRISPR technology and functional genomics are accelerating our understanding of this process, offering new opportunities for drug discovery and immunotherapy development.
References
- 1. Morotti M et al.. 2024. PGE(2) inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function.. Nature 629(8011):426-434 PMID: 38658764
- 2. Sierro-Martínez B et al.. 2025. Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies.. J Transl Med 23(1):942 PMID: 40830482
- 3. Saxena M et al.. 1998. Negative regulation of T cell antigen receptor signal transduction by hematopoietic tyrosine phosphatase (HePTP).. J Biol Chem 273(25):15340-4 PMID: 9624114
- 4. Ohteki T et al.. 2000. Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3.. J Exp Med 192(1):99-104 PMID: 10880530
- 5. Li J et al.. 2016. EBI2 augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells.. Nature 533(7601):110-4 PMID: 27147029
- 6. Cheung KL et al.. 2024. Class IIa HDAC4 and HDAC7 cooperatively regulate gene transcription in Th17 cell differentiation.. Proc Natl Acad Sci U S A 121(18):e2312111121 PMID: 38657041
- 7. Kumar A et al.. 1987. Evidence for negative regulation of T cell growth by low affinity interleukin 2 receptors.. J Immunol 138(5):1485-93 PMID: 3100639
- 8. Barnes MJ et al.. 2018. Lysophosphatidylserine suppression of T-cell activation via GPR174 requires Gαs proteins.. Immunol Cell Biol 96(4):439-445 PMID: 29457279
